Department of Health and Human Services, Office of HIV/AIDS and Infectious Disease Policy, 200 Independence Avenue SW, Room 443–H, Washington, DC 20201.

FOR FURTHER INFORMATION CONTACT: Ms. Caroline Talev, Public Health Assistant, PACHA, Department of Health and Human Services, 200 Independence Avenue SW, Room 443–H, Washington, DC 20201; (202) 205–1178. More detailed information about PACHA can be obtained by accessing the Council's Web site *www.aids.gov/pacha.*

SUPPLEMENTARY INFORMATION: The PACHA was established to provide advice, information, and recommendations to the Secretary regarding programs and policies intended to promote effective prevention of HIV disease and AIDS. The functions of the Council are solely advisory in nature.

The Council consists of not more than 25 members. Council members are selected from prominent community leaders with particular expertise in, or knowledge of, matters concerning HIV and AIDS, public health, global health, philanthropy, marketing or business, as well as other national leaders held in high esteem from other sectors of society. Council members are appointed by the Secretary or designee, in consultation with the White House Office on National AIDS Policy. Pursuant to advance written agreement, Council members shall receive no stipend for the advisory service they render as members of PACHA. However, as authorized by law and in accordance with federal travel regulations, PACHA members may receive per diem and reimbursement for travel expenses incurred in relation to performing duties for the Council.

This announcement is to solicit nominations of qualified candidates to fill current vacancies on the PACHA.

Nominations

In accordance with the PACHA charter, persons nominated for appointment as members of the PACHA should be among prominent community leaders and authorities with particular expertise in, or knowledge of, matters concerning HIV and AIDS, public health, global health, philanthropy, marketing or business, as well as other national leaders held in high esteem from other sectors of society. The following information should be included in the package of material submitted for each individual being nominated for consideration of appointment:

a. The name, return address, daytime telephone number, and affiliation(s) of the individual being nominated, the basis for the individual's nomination, and a statement bearing an original signature of the nominated individual that, if appointed, he or she is willing to serve as a member of the Council;

b. the name, return address, and daytime telephone number at which the nominator may be contacted. Organizational nominators must identify a principal contact person; and

c. a copy of a current resume or curriculum vitae for the nominated individual.

Individuals can nominate themselves for consideration of appointment to the Council. All nominations must include the required information. Incomplete nominations will not be processed for consideration. The letter from the nominator and certification of the nominated individual must bear original signatures; reproduced copies of these signatures are not acceptable.

The Department is legally required to ensure that the membership of HHS federal advisory committees is fairly balanced in terms of points of view represented and the functions to be performed by the advisory committee. Every effort is made to ensure that the views of women, all ethnic and racial groups, and people with disabilities are represented on HHS federal advisory committees and, therefore, the Department encourages nominations of qualified candidates from these groups. The Department also encourages geographic diversity in the composition of the Council. Appointment to the Council shall be made without discrimination on the basis of age, race, ethnicity, gender, sexual orientation, disability, and cultural, religious, or socioeconomic status. The Standards of Ethical Conduct for Employees of the Executive Branch are applicable to individuals who are appointed as members of the Council.

Dated: February 22, 2013.

B. Kaye Hayes,

Executive Director, Presidential Advisory Council on HIV/AIDS.

[FR Doc. 2013–05218 Filed 3–6–13; 8:45 am]

BILLING CODE 4150–43–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

Submission for OMB Review; Comment Request

Title: Community Services Block Grant (CSBG) Program Model Plan Application.

OMB No.: 0970–0382.

Description: Sections 676 and 677 of the Community Services Block Grant Act require States, including the District of Columbia and the Commonwealth of Puerto Rico, Tribes, Tribal organizations and U.S. territories applying for Community Services Block Grant (CSBG) funds to submit an application and plan (Model Application Plan). The application plan must meet statutory requirements prior to being funded with CSBG funds. Applicants have the option to submit a detailed application annually or biannually. Entities that submit a biannual application must provide an abbreviated application the following year if substantial changes to the initial application will occur. OMB approval is being sought.

Respondents: State Governments, including the District of Columbia and the Commonwealth of Puerto Rico, Tribal Governments, Tribal Organizations, and U.S. territories.

ANNUAL BURDEN ESTIMATES

Instrument	Number of respondents	Number of responses per respondent	Average burden hours per response	Total burden hours
Model State CSBG Application	56	1	10	560
Model Indian Tribes & Tribal Organizations CSBG Application	30	1	10	300

Estimated Total Annual Burden Hours: 860.

Additional Information: Copies of the proposed collection may be obtained by writing to the Administration for Children and Families, Office of Planning, Research and Evaluation, 370 L'Enfant Promenade SW., Washington,

DC 20447, Attn: ACF Reports Clearance Officer. All requests should be identified by the title of the information collection. Email address: *infocollection@acf.hhs.gov.*

OMB Comment: OMB is required to make a decision concerning the collection of information between 30 and 60 days after publication of this document in the **Federal Register**. Therefore, a comment is best assured of having its full effect if OMB receives it within 30 days of publication. Written comments and recommendations for the proposed information collection should be sent directly to the following: Office of Management and Budget, Paperwork Reduction Project, Fax: 202–395–7285, Email: *OIRA_SUBMISSION@OMB.EOP.GOV,* Attn: Desk Officer for the Administration for Children and Families.

Robert Sargis,

Reports Clearance Officer.

[FR Doc. 2013–05331 Filed 3–6–13; 8:45 am]

BILLING CODE 4184–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2012–N–1046]

Veterinary Oversight of Antimicrobial Use in Livestock: Impact on Stakeholders; Public Meetings; Request for Comments

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of public meetings; request for comments.

SUMMARY: The Food and Drug Administration (FDA) is announcing plans for five meetings to provide an opportunity for public dialogue and feedback on challenges faced by the animal agriculture industry and practicing veterinarians as FDA implements its initiative for the judicious use of medically important antimicrobials in medicated feed or drinking water of food-producing animals. Particular emphasis will be placed on challenges faced by animal producers in areas that may lack access to adequate veterinary services. The meetings are jointly sponsored by FDA and the U.S. Department of Agriculture's (USDA's) Animal and Plant Health Inspection Service (APHIS).

DATES: See the **SUPPLEMENTARY INFORMATION** section for meeting dates.

FOR FURTHER INFORMATION CONTACT: Patricia Arnwine, Center for Veterinary Medicine (HFV–6), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855; 240–276–9724; FAX: 240–276–9101, *patricia.arnwine@fda.hhs.gov.*

SUPPLEMENTARY INFORMATION:

Dates, Times, and Locations

- April 9, 2013, from 8:30 a.m. to 12:30 p.m., Western Kentucky University–Carroll Knicely Conference Center (Auditorium rm. 138), 2355 Nashville Rd., Bowling Green, KY 42101; 270–745–1908; FAX: 270–745–1911; *http://www.wku.edu/.*
- April 23, 2013, from 8:30 a.m. to 12:30 p.m., Evergreen State College (Library 4300), 2700 Evergreen Pkwy. NW., Olympia WA 98505; 360–867–6192 or 6000; *http://www.evergreen.edu/home.htm.*
- May 8, 2013, from 8:30 a.m. to 12:30 p.m., The Natural Resource Research Center, USDA Animal and Plant Health & Inspection Service, Veterinary Services, Centers for Epidemiology & Animal Health, 2150 Centre Ave. (Building B, Gray's Peak Conference Rooms A & B), Fort Collins, CO 80526–8117; 970–494–7200; FAX: 970–472–2668; *http://www.aphis.usda.gov/about_aphis/programs_offices/veterinary_services/ceah.shtml.*
- May 21, 2013, from 8:30 a.m. to 12:30 p.m., Best Western Ramkota Hotel & Conference Center (Amphitheater II), 920 West Sioux Ave., Pierre, SD 57501; 605–224–6877; FAX: 605–224–1042; *http://pierre.bwramkota.com/.*
- June 4, 2013, from 8:30 a.m. to 12:30 p.m., Texas A&M University (Memorial Student Center, rm. 2406A), Joe Routt Boulevard and Houston Street, College Station, TX 77840; 979–845–8904; FAX: 979–845–2519; *http://www.tamu.edu/.*

Oral Presentations: Interested persons may make oral presentations on the topic of the discussion of the meeting. Oral presentations from the public during the open public comment period will be scheduled approximately:

- April 9, 2013, from 9:45 a.m. to 11 a.m. on the day of the meeting in Bowling Green, KY;
- April 23, 2013, from 9:45 a.m. to 11 a.m. on the day of the meeting in Olympia, WA;
- May 8, 2013, from 9:45 a.m. to 11 a.m. on the day of the meeting in Fort Collins, CO;
- May 21, 2013, from 9:45 a.m. to 11 a.m. on the day of the meeting in Pierre, SD; and
- June 4, 2013, from 9:45 a.m. to 11 a.m. on the day of the meeting in College Station, TX.

Although prior notification is not required, it is recommended that those desiring to make oral presentations notify the contact person before the meeting. In an effort to accommodate all who desire to speak, time allotted for each presentation may be limited.

Registration is not required for these meetings; however, early arrival is recommended because seating may be limited. If you need special accommodations due to a disability, please contact FDA (see **FOR FURTHER INFORMATION CONTACT**) at least 7 days in advance.

Comments: Regardless of attendance at the public meetings, interested persons may submit either electronic or written comments regarding the topics to be discussed at these meetings. Submit electronic comments to *http://www.regulations.gov.* Submit written comments to the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. It is only necessary to send one set of comments. Identify comments with the docket number found in brackets in the heading of this document. Received comments may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday. The docket will remain open for written or electronic comments for 60 days following the last of these five meetings.

FDA is concerned about the risk that antimicrobial resistance poses to public health from the use of medically important antimicrobial drugs in food-producing animals. Over the past several years, FDA's Center for Veterinary Medicine has developed a policy framework for decreasing this public health risk through the application of concepts of judicious use. Among these concepts, FDA believes that it is important to include veterinary oversight in the use of medically important antimicrobial drugs in the feed or water of food-producing animals to assure the drugs' appropriate and judicious use.

Until the early 1990s, most antimicrobial drugs were approved for over-the-counter (OTC) use in food-producing animals. However, since that time increasing concerns about antimicrobial resistance and evolving understanding of the science related to the issue have resulted in greater scrutiny of the conditions under which these drugs are approved. As a result, since the early 1990s all new approvals for antimicrobial drug products for use in food-producing animals have been